Personality Tied to Cardiovascular Disease Risk With Type 2 Diabetes
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 17, 2024 -- Personality traits can influence cardiovascular disease (CVD) risk with type 2 diabetes mellitus (T2DM), according to a study published online Sept. 10 in BMJ Open Diabetes Research & Care.
Chan Soon Park, from Seoul National University Hospital in South Korea, and colleagues used data from 8,794 patients with T2DM participating in the U.K. Biobank (2006 to 2010 with follow-up through 2021) to understand the prognostic value of personality (sociability, warmth, diligence, curiosity, and nervousness) and its association with lifestyle factors.
The researchers found that during a median of 13.6 years of follow-up, diligence was significantly associated with a reduced risk for incident CVD. A trend toward lower incidence was seen for the composite outcome (adjusted hazard ratio, 0.93), as well as individual components: myocardial infarction, ischemic stroke, atrial fibrillation, and heart failure. For both high and low diligence, healthy lifestyle behaviors significantly reduced the risk for composite CVDs in groups. A structural equation model showed that diligence directly affected the risk for the primary outcome or indirectly by modifying lifestyle behaviors.
"These findings highlight the importance of assessing personality traits for cardiovascular risk prediction and modifying lifestyle factors as preventive strategies for patients with T2DM," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-18 06:00
Read more
- Flavored Vapes Behind Big Surge in U.S. E-Cigarette Sales
- Expanded Admission Screening Protocol for Candida Auris Beneficial
- Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
- FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
- Small but Important Differences Seen Between Rosuvastatin, Atorvastatin
- Even 'Weekend Warrior' Exercise Can Keep Your Brain Healthy
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions